Novartis Contract Manufacturing Capacity Update October 2024: Large Molecule Drug Substance

This presentation offers a comprehensive overview of Novartis's mammalian development services, manufacturing solutions, and accessible manufacturing sites available to external clients.

As Novartis continues to expand its mammalian production capacity across its global manufacturing network, this session will also provide valuable updates on upcoming completion dates and newly available capacity, giving clients insights into how Novartis can support their development and manufacturing needs at every stage.